BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35526267)

  • 1. Molecular and clinical characteristics of IDH mutations in Chinese NSCLC patients and potential treatment strategies.
    Chen S; Zhu H; Jin M; Yuan H; Liu Z; Li J; Zhang X; Meng L; Li T; Diao Y; Gao H; Hong C; Zhu X; Zheng J; Li F; Niu Y; Ma T; Li X
    Cancer Med; 2022 Nov; 11(22):4122-4133. PubMed ID: 35526267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation.
    Yamaguchi S; Iwanaga E; Tokunaga K; Nanri T; Shimomura T; Suzushima H; Mitsuya H; Asou N
    Eur J Haematol; 2014 Jun; 92(6):471-7. PubMed ID: 24443894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Analysis of IDH1 and IDH2 mutations in patients with acute myeloid leukemia].
    Jia ZX; Zhou M; Chao HY; Lu XZ; Zhang R; Cen L; Xiao R; Jiang NK
    Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):397-401. PubMed ID: 22781800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
    Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
    J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation.
    Bill M; Jentzsch M; Bischof L; Kohlschmidt J; Grimm J; Schmalbrock LK; Backhaus D; Brauer D; Goldmann K; Franke GN; Vucinic V; Niederwieser D; Mims AS; Platzbecker U; Eisfeld AK; Schwind S
    Blood Adv; 2023 Feb; 7(3):436-444. PubMed ID: 35381077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
    Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
    J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical characteristics in adult acute myeloid leukemia with isocitrate dehydrogenase gene mutation].
    Wang RX; Wu DP; Chen SN; He J; Xu Y; Wang XL; Yin J; Tian H; Tian XP; Sun AN
    Zhonghua Yi Xue Za Zhi; 2013 Mar; 93(10):751-5. PubMed ID: 23755812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML.
    DiNardo CD; Ravandi F; Agresta S; Konopleva M; Takahashi K; Kadia T; Routbort M; Patel KP; Mark Brandt ; Pierce S; Garcia-Manero G; Cortes J; Kantarjian H
    Am J Hematol; 2015 Aug; 90(8):732-6. PubMed ID: 26016821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia.
    Lu J; Chen M; Hua H; Qin W; Zhang R; Lu X; Chao H
    Int J Lab Hematol; 2021 Dec; 43(6):1483-1490. PubMed ID: 34270876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IDH mutations in glioma and acute myeloid leukemia.
    Dang L; Jin S; Su SM
    Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
    Shoukier M; Kadia T; Konopleva M; Alotaibi AS; Alfayez M; Loghavi S; Patel KP; Kanagal-Shamanna R; Cortes J; Samra B; Jabbour E; Garcia-Manero G; Takahashi K; Pierce S; Short NJ; Yilmaz M; Sasaki K; Masarova L; Pemmaraju N; Borthakur G; Kantarjian HM; Ravandi F; DiNardo CD; Daver N
    Cancer; 2021 Feb; 127(3):381-390. PubMed ID: 33119202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic significance of different IDH mutations and accompanying gene mutations in patients with acute myeloid leukemia].
    Wu RY; Xie XS; Wei Y; Jang ZX; Chen DD; Sun H; Wan DM; Liu YF; Sun L
    Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):39-44. PubMed ID: 33677867
    [No Abstract]   [Full Text] [Related]  

  • 13. Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
    Chen EC; Li S; Eisfeld AK; Luskin MR; Mims A; Jones D; Antin JH; Cutler CS; Koreth J; Ho VT; Gooptu M; Romee R; El-Jawahri A; McAfee SL; DeFilipp Z; Soiffer RJ; Chen YB; Fathi AT
    Transplant Cell Ther; 2021 Jun; 27(6):479.e1-479.e7. PubMed ID: 33840625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution.
    Rodriguez EF; De Marchi F; Lokhandwala PM; Belchis D; Xian R; Gocke CD; Eshleman JR; Illei P; Li MT
    Cancer Med; 2020 Jun; 9(12):4386-4394. PubMed ID: 32333643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDH mutations in acute myeloid leukemia.
    Rakheja D; Konoplev S; Medeiros LJ; Chen W
    Hum Pathol; 2012 Oct; 43(10):1541-51. PubMed ID: 22917530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isocitrate dehydrogenase inhibitors in acute myeloid leukemia.
    Liu X; Gong Y
    Biomark Res; 2019; 7():22. PubMed ID: 31660152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IDH mutations in cancer and progress toward development of targeted therapeutics.
    Dang L; Yen K; Attar EC
    Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders.
    Zou Y; Zeng Y; Zhang DF; Zou SH; Cheng YF; Yao YG
    Biochem Biophys Res Commun; 2010 Nov; 402(2):378-83. PubMed ID: 20946881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular evaluation of DNMT3A and IDH1/2 gene mutation: frequency, distribution pattern and associations with additional molecular markers in normal karyotype Indian acute myeloid leukemia patients.
    Ahmad F; Mohota R; Sanap S; Mandava S; Das BR
    Asian Pac J Cancer Prev; 2014; 15(3):1247-53. PubMed ID: 24606448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.